Date
Title
Jul 24, 2017

Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective

Jul 21, 2017

Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing

Jun 28, 2017

Innocoll Announces Scheme Meeting and Extraordinary General Meeting Voting Results

May 30, 2017

Innocoll and Gurnet Point Announce Dispatch of Rule 15 Proposals

May 12, 2017

Innocoll Announces Proxy Statement Mail-Out to Shareholders

May 10, 2017

Innocoll Announces Scheme Meeting Details

Apr 04, 2017

Gurnet Point L.P. enters into agreement to acquire Innocoll Holdings plc

Mar 29, 2017

Innocoll announces regulatory path forward after receiving formal FDA Type A meeting minutes regarding its XARACOLL® (bupivacaine HCl collagen-matrix implant) New Drug Application

Mar 16, 2017

Innocoll Holdings plc Announces Fourth Quarter and Full-Year 2016 Financial and Operating Results and Provides Corporate Update

Mar 16, 2017

Innocoll Holdings Announces Statement re: Possible Offer

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited